Lenvatinib Rechallenge in a Patient with Advanced Thymic Carcinoma: A Case Report

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2022 Oct 17

PMID 36251511

Authors

Yuto Terashima

Taiki Hakozaki

Susumu Takeuchi

Yukio Hosomi

Affiliations

Soon will be listed here.

Abstract

Advanced thymic carcinomas have limited treatment options. Recently, lenvatinib was approved for advanced thymic carcinoma treatment. However, the clinical benefit of lenvatinib re-administration in patients with advanced thymic carcinoma who developed prior lenvatinib treatment resistance (lenvatinib rechallenge) remains unclear. Here, we present a case treated with lenvatinib rechallenge for advanced thymic carcinoma who was previously treated with lenvatinib as the second-line treatment followed by multiple cytotoxic agents. Disease control rapidly deteriorated after the eighth line of treatment because of uncontrollable right pleural and pericardial effusion, which required repeated thoracic and pericardial drainage. Shortly after lenvatinib re-administration, rapid pleural and pericardial effusion reduction was observed. Thereafter, the patient achieved sustained clinical response with good pleural and pericardial effusion control for approximately 7 months. Our case might suggest lenvatinib rechallenge as a treatment option for patients with advanced thymic carcinoma, especially those with poor pleural and pericardial effusion control.

Citing Articles

Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer.

Yokota T, Hamauchi S, Kawakami T, Fushiki K Invest New Drugs. 2024; 42(4):361-368.

PMID: 38809355 DOI: 10.1007/s10637-024-01449-9.

Successful resection after first-line lenvatinib therapy in an advanced thymic carcinoma.

Shimura M, Miura K, Koizumi T, Kanda S, Mishima S, Hara D Thorac Cancer. 2023; 14(17):1640-1643.

PMID: 37132133 PMC: 10260480. DOI: 10.1111/1759-7714.14913.

Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report.

Terashima Y, Hakozaki T, Takeuchi S, Hosomi Y Thorac Cancer. 2022; 13(23):3408-3411.

PMID: 36251511 PMC: 9715831. DOI: 10.1111/1759-7714.14699.

References

Terashima Y, Hakozaki T, Takeuchi S, Hosomi Y . Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report. Thorac Cancer. 2022; 13(23):3408-3411. PMC: 9715831. DOI: 10.1111/1759-7714.14699. View

Felicetti F, Nervo A, Piovesan A, Berardelli R, Marchisio F, Gallo M . Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer. Expert Rev Anticancer Ther. 2017; 17(12):1093-1098. DOI: 10.1080/14737140.2017.1390432. View

Buonerba C, Di Lorenzo G . Efficacy of sunitinib rechallenge in kidney cancer: are mTOR inhibitors involved or is it only a matter of time?. Onkologie. 2011; 34(6):295-6. DOI: 10.1159/000328800. View

Ueda T, Tsubamoto H, Eguchi A, Terada T, Shibahara H . Bevacizumab helped resolve pericardial and pleural effusion that was associated with malignant ovarian clear cell carcinoma. Gynecol Oncol Rep. 2016; 16:11-3. PMC: 4899409. DOI: 10.1016/j.gore.2016.01.006. View

Sato J, Satouchi M, Itoh S, Okuma Y, Niho S, Mizugaki H . Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. Lancet Oncol. 2020; 21(6):843-850. DOI: 10.1016/S1470-2045(20)30162-5. View

Margaritora S, Cesario A, Cusumano G, Meacci E, DAngelillo R, Bonassi S . Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. Ann Thorac Surg. 2010; 89(1):245-52. DOI: 10.1016/j.athoracsur.2009.08.074. View

Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S . Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v40-55. DOI: 10.1093/annonc/mdv277. View

Zama I, Hutson T, Elson P, Cleary J, Choueiri T, Heng D . Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer. 2010; 116(23):5400-6. DOI: 10.1002/cncr.25583. View

de Jong W, Blaauwgeers J, Schaapveld M, Timens W, Klinkenberg T, Groen H . Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer. 2007; 44(1):123-30. DOI: 10.1016/j.ejca.2007.11.004. View

10.

Katsuya Y, Horinouchi H, Seto T, Umemura S, Hosomi Y, Satouchi M . Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. Eur J Cancer. 2019; 113:78-86. DOI: 10.1016/j.ejca.2019.03.012. View

11.

Miyake H, Harada K, Fujisawa M . Promising response to axitinib rechallenge for metastatic renal cell carcinoma after progression on prior axitinib: report of two cases. Int Cancer Conf J. 2019; 7(1):30-34. PMC: 6498296. DOI: 10.1007/s13691-017-0313-y. View

12.

Komatsu S, Yano Y, Kido M, Kuramitsu K, Gon H, Fukushima K . Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma. Anticancer Res. 2021; 41(9):4555-4562. DOI: 10.21873/anticanres.15268. View

13.

Chen D, Zhang Y, Shi F, Li M, Zhu H, Kong L . Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review. Onco Targets Ther. 2015; 8:2767-70. PMC: 4599051. DOI: 10.2147/OTT.S90145. View

14.

Oudard S, Vano Y . The role of rechallenge with targeted therapies in metastatic renal-cell carcinoma. Curr Opin Urol. 2015; 25(5):402-10. DOI: 10.1097/MOU.0000000000000206. View

15.

Falkson C, Vella E, Ellis P, Maziak D, Ung Y, Yu E . Surgical, Radiation, and Systemic Treatments of Patients With Thymic Epithelial Tumors: A Clinical Practice Guideline. J Thorac Oncol. 2022; 17(11):1258-1275. DOI: 10.1016/j.jtho.2022.08.007. View

16.

Engels E, Pfeiffer R . Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer. 2003; 105(4):546-51. DOI: 10.1002/ijc.11099. View

17.

Takinami M, Yokota T . Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma. Case Rep Oncol. 2020; 13(2):522-527. PMC: 7265699. DOI: 10.1159/000507344. View

18.

Ettinger D, Riely G, Akerley W, Borghaei H, Chang A, Cheney R . Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2013; 11(5):562-76. DOI: 10.6004/jnccn.2013.0072. View

19.

Nie K, Zhang Z, You Y, Zhuang X, Zhang C, Ji Y . A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer. Thorac Cancer. 2019; 11(1):8-14. PMC: 6938744. DOI: 10.1111/1759-7714.13238. View

20.

Noro R, Kobayashi K, Usuki J, Yomota M, Nishitsuji M, Shimokawa T . Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B. Thorac Cancer. 2020; 11(7):1876-1884. PMC: 7327672. DOI: 10.1111/1759-7714.13472. View